These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 32404198)

  • 41. Combination therapy with zoledronic acid and cetuximab effectively suppresses growth of colorectal cancer cells regardless of KRAS status.
    Kato J; Futamura M; Kanematsu M; Gaowa S; Mori R; Tanahashi T; Matsuhashi N; Yoshida K
    Int J Cancer; 2016 Mar; 138(6):1516-27. PubMed ID: 26437179
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Higher metastatic efficiency of KRas G12V than KRas G13D in a colorectal cancer model.
    Alamo P; Gallardo A; Di Nicolantonio F; Pavón MA; Casanova I; Trias M; Mangues MA; Lopez-Pousa A; Villaverde A; Vázquez E; Bardelli A; Céspedes MV; Mangues R
    FASEB J; 2015 Feb; 29(2):464-76. PubMed ID: 25359494
    [TBL] [Abstract][Full Text] [Related]  

  • 43.
    Ye S; Hu X; Ni C; Jin W; Xu Y; Chang L; Zhou H; Jiang J; Yang L
    Mol Cancer Ther; 2020 Mar; 19(3):956-965. PubMed ID: 31924740
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Lauric acid can improve the sensitization of Cetuximab in KRAS/BRAF mutated colorectal cancer cells by retrievable microRNA-378 expression.
    Weng WH; Leung WH; Pang YJ; Hsu HH
    Oncol Rep; 2016 Jan; 35(1):107-16. PubMed ID: 26496897
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Low‑dose trametinib and Bcl‑xL antagonist have a specific antitumor effect in KRAS‑mutated colorectal cancer cells.
    Koyama M; Kitazawa M; Nakamura S; Matsumura T; Miyazaki S; Miyagawa Y; Muranaka F; Tokumaru S; Okumura M; Yamamoto Y; Ehara T; Hondo N; Takahata S; Takeoka M; Miyagawa SI; Soejima Y
    Int J Oncol; 2020 Nov; 57(5):1179-1191. PubMed ID: 32901840
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Influence of KRAS p.G13D mutation in patients with metastatic colorectal cancer treated with cetuximab.
    Gajate P; Sastre J; Bando I; Alonso T; Cillero L; Sanz J; Caldés T; Díaz-Rubio E
    Clin Colorectal Cancer; 2012 Dec; 11(4):291-6. PubMed ID: 22537608
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Gene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance).
    Cushman SM; Jiang C; Hatch AJ; Shterev I; Sibley AB; Niedzwiecki D; Venook AP; Owzar K; Hurwitz HI; Nixon AB
    Clin Cancer Res; 2015 Mar; 21(5):1078-86. PubMed ID: 25520391
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the KRAS G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study.
    Segelov E; Thavaneswaran S; Waring PM; Desai J; Robledo KP; Gebski VJ; Elez E; Nott LM; Karapetis CS; Lunke S; Chantrill LA; Pavlakis N; Khasraw M; Underhill C; Ciardiello F; Jefford M; Wasan H; Haydon A; Price TJ; van Hazel G; Wilson K; Simes J; Shapiro JD
    J Clin Oncol; 2016 Jul; 34(19):2258-64. PubMed ID: 27114605
    [TBL] [Abstract][Full Text] [Related]  

  • 49. KRAS mutation confers resistance to antibody-dependent cellular cytotoxicity of cetuximab against human colorectal cancer cells.
    Nakadate Y; Kodera Y; Kitamura Y; Shirasawa S; Tachibana T; Tamura T; Koizumi F
    Int J Cancer; 2014 May; 134(9):2146-55. PubMed ID: 24136682
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Meta-analysis comparing the efficacy of anti-EGFR monoclonal antibody therapy between KRAS G13D and other KRAS mutant metastatic colorectal cancer tumours.
    Rowland A; Dias MM; Wiese MD; Kichenadasse G; McKinnon RA; Karapetis CS; Sorich MJ
    Eur J Cancer; 2016 Mar; 55():122-30. PubMed ID: 26812186
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Discernment between candidate mechanisms for KRAS G13D colorectal cancer sensitivity to EGFR inhibitors.
    McFall T; Schomburg NK; Rossman KL; Stites EC
    Cell Commun Signal; 2020 Nov; 18(1):179. PubMed ID: 33153459
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Targeting antioxidant enzymes enhances the therapeutic efficacy of the BCL-X
    Oh Y; Jung HR; Min S; Kang J; Jang D; Shin S; Kim J; Lee SE; Sung CO; Lee WS; Lee C; Jeong EM; Cho SY
    Cancer Lett; 2021 Jan; 497():123-136. PubMed ID: 33068701
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The YAP1/SIX2 axis is required for DDX3-mediated tumor aggressiveness and cetuximab resistance in
    Wu DW; Lin PL; Wang L; Huang CC; Lee H
    Theranostics; 2017; 7(5):1114-1132. PubMed ID: 28435452
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Unstable Genome and Transcriptome Dynamics during Tumor Metastasis Contribute to Therapeutic Heterogeneity in Colorectal Cancers.
    Cho SY; Chae J; Na D; Kang W; Lee A; Min S; Kang J; Choi B; Lee J; Sung CO; Chuang JH; Lee C; Lee WS; Park H; Kim JI
    Clin Cancer Res; 2019 May; 25(9):2821-2834. PubMed ID: 30670495
    [TBL] [Abstract][Full Text] [Related]  

  • 55. GC1118, a novel anti-EGFR antibody, has potent KRAS mutation-independent antitumor activity compared with cetuximab in gastric cancer.
    Park JE; Jin MH; Hur M; Nam AR; Bang JH; Won J; Oh DY; Bang YJ
    Gastric Cancer; 2019 Sep; 22(5):932-940. PubMed ID: 30815759
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antitumor activity of the aurora a selective kinase inhibitor, alisertib, against preclinical models of colorectal cancer.
    Pitts TM; Bradshaw-Pierce EL; Bagby SM; Hyatt SL; Selby HM; Spreafico A; Tentler JJ; McPhillips K; Klauck PJ; Capasso A; Diamond JR; Davis SL; Tan AC; Arcaroli JJ; Purkey A; Messersmith WA; Ecsedy JA; Eckhardt SG
    Oncotarget; 2016 Aug; 7(31):50290-50301. PubMed ID: 27385211
    [TBL] [Abstract][Full Text] [Related]  

  • 57. MicroRNA-425-5p Expression Affects BRAF/RAS/MAPK Pathways In Colorectal Cancers.
    Angius A; Pira G; Scanu AM; Uva P; Sotgiu G; Saderi L; Manca A; Serra C; Uleri E; Piu C; Caocci M; Ibba G; Zinellu A; Cesaraccio MR; Sanges F; Muroni MR; Dolei A; Cossu-Rocca P; De Miglio MR
    Int J Med Sci; 2019; 16(11):1480-1491. PubMed ID: 31673240
    [TBL] [Abstract][Full Text] [Related]  

  • 58. SLC25A22 Promotes Proliferation and Survival of Colorectal Cancer Cells With KRAS Mutations and Xenograft Tumor Progression in Mice via Intracellular Synthesis of Aspartate.
    Wong CC; Qian Y; Li X; Xu J; Kang W; Tong JH; To KF; Jin Y; Li W; Chen H; Go MY; Wu JL; Cheng KW; Ng SS; Sung JJ; Cai Z; Yu J
    Gastroenterology; 2016 Nov; 151(5):945-960.e6. PubMed ID: 27451147
    [TBL] [Abstract][Full Text] [Related]  

  • 59. In vivo and ex vivo cetuximab sensitivity assay using three-dimensional primary culture system to stratify KRAS mutant colorectal cancer.
    Tashiro T; Okuyama H; Endo H; Kawada K; Ashida Y; Ohue M; Sakai Y; Inoue M
    PLoS One; 2017; 12(3):e0174151. PubMed ID: 28301591
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Phase II study of single-agent cetuximab in KRAS G13D mutant metastatic colorectal cancer.
    Schirripa M; Loupakis F; Lonardi S; Cremolini C; Bergamo F; Zagonel V; Falcone A
    Ann Oncol; 2015 Dec; 26(12):2503. PubMed ID: 26371285
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.